GCGeorge Chrisafis

George Chrisafis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


George Chrisafis has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer

    by Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, et al.

    Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133

  • Open Access

    Supplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer

    by Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, et al.

    Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens

  • Open Access

    Supplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer

    by Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, et al.

    Trial Schema; Gating strategy; KEY RESOURCES table


  • Open Access

    Supplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer

    by Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, et al.

    Clinical Trial Protocol, IRB amendments and DSMB recommendations

  • Open Access

    Hepatobiliary Progenitor-like Reprogramming in Liver Metastases

    by Ajit Kumar Sharma, Nobuyuki Takahashi, Yingying Cao, Abhinav Joshi, Sophie Zhuang, Amira Kazi, Michael Nirula, Sarthak Sahoo, Yang Zhang, Rajesh Kumar, et al.

    Metastatic progression requires cancer cells to adapt to the unique constraints of distant organ microenvironments, yet the mechanisms that drive organ-specific adaptations remain poorly understood. Here, we show that the liver actively rewrites metastatic cancer cell identity, driving tumor cells toward a hepatobiliary progenitor-like state. Through integrated transcriptomic, proteomic, metabolomic, and epigenomic analyses of patient-derived rapid-autopsy samples and experimental models, we identify this state as selectively enriched in liver metastases. It is characterized by co-activation of hepatic and biliary/progenitor regulators HNF4A and SOX9 and is observed across multiple epithelial cancers, indicating a conserved response to the hepatic niche. Mechanistically, hepatocyte-derived TGF-β and hypoxia converge to activate a HIF-1α-ACLY axis, increasing nuclear acetyl-coenzyme A availability and histone acetylation at hepatic lineage regulatory elements to drive hepatobiliary reprogramming. This coordinated niche-response program can be captured transcriptionally and is associated with inferior overall survival. Disruption of this pathway suppresses hepatic reprogramming and impairs liver metastatic fitness. These findings identify the liver as an active determinant of metastatic cell fate, linking microenvironmental signaling to metabolic and chromatin remodeling programs that enable lineage plasticity. More broadly, they reveal organ-specific reprogramming as a fundamental principle of metastasis and a therapeutic vulnerability in liver metastases.

  • Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer

    by Brett A. Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang, Min-Jung Lee, Sarthak Sahoo, Renee N. Donahue, Rajesh Kumar, Michael Nirula, et al.

    Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.